Submissions for variant NM_000350.3(ABCA4):c.5882G>A (p.Gly1961Glu)

gnomAD frequency: 0.00269  dbSNP: rs1800553

Total submissions: 57

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Eurofins Ntd Llc (ga)	RCV000078670	SCV000110529	pathogenic	not provided	2016-11-30	criteria provided, single submitter	clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000787514	SCV000221171	pathogenic	Stargardt disease	2020-05-28	criteria provided, single submitter	clinical testing	The p.Gly1961Glu (NM_000350.2 c.5882G>A) variant in ABCA4 has been reported >20 individuals with Stargardt disease and other retinal phenotypes and segregated with disease in 5 affected individuals from 5 families, but has been associated with reduced penetrance (Allikmets 1997 PMID:9295268, Burke 2012 PMID:22312191, Burke 2012 PMID:22661473, Song 2011 PMID:22025579, Burke 2010 PMID:20696155, Wiszniewski 2005 PMID:16103129, Cella 2009 PMID:19217903, Cideciyan 2009 PMID: 19074458). The variant shows a statistically significant (p<0.0001) difference in allele frequency in cases (5%) compared to the general population (0.4%, http://gnomad.broadinstitute.org). In vitro functional studies support an impact on protein function (Sun 2000 PMID:11017087). This variant has also been reported as Pathogenic by multiple clinical labs in ClinVar (Variation ID 7879). In summary, this variant meets criteria to be classified as pathogenic for Stargardt disease in an autosomal recessive manner, though it may show reduced penetrance and a milder clinical presentation compared to other pathogenic variants in the ABCA4 gene. ACMG/AMP Criteria applied: PS3_Supporting, PM3_VeryStrong, PP1_Strong.
Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine	RCV000008340	SCV000267674	likely pathogenic	Severe early-childhood-onset retinal dystrophy		criteria provided, single submitter	research	identified in compound heterozygous state in affected individual/s with macular isease
Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg	RCV000008340	SCV000281939	pathogenic	Severe early-childhood-onset retinal dystrophy	2016-01-01	criteria provided, single submitter	clinical testing
GeneDx	RCV000078670	SCV000321357	pathogenic	not provided	2022-04-12	criteria provided, single submitter	clinical testing	Published functional studies demonstrate this variant results in reduced ATPase activity (Sun et al., 2000); Reported as pathogenic in ClinVar by different clinical laboratories but additional evidence is not available (ClinVar Variation ID: 7888; ClinVar); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25921964, 25082885, 26593885, 28611652, 9295268, 22661473, 31980526, 32581362, 31589614, 32000842, 32619608, 33090715, 32783370, 32815999, 33301772, 32037395, 10958763, 15614537, 21786275, 16103129, 22025579, 22264887, 24265693, 25097241, 25087612, 11017087, 19217903, 25640233, 27775217, 27884173, 27535533, 26247787, 27414126, 28327576, 28044389, 29555955, 28130426, 29847635, 28224992, 30060493, 28181551, 29114839, 28492530, 28118664, 29769798, 28157192, 30609409, 30924848, 29925512, 30718709, 29765157, 28559085, 30156925, 18161617, 31814694, 32141364, 31456290, 32036094, 32845068, 34327195, 34426522, 33909047, 34008892, 33302505, 31573552)
Illumina Laboratory Services, Illumina	RCV000273328	SCV000359235	pathogenic	ABCA4-related disorder	2017-05-08	criteria provided, single submitter	clinical testing	The ABCA4 c.5882G>A (p.Gly1961Glu) missense variant has been reported in at least eight studies in which it is found in over 50 individuals, 54 of whom were diagnosed with Stargardt disease, including 18 who carry the variant in a homozygous state, in at least 26 who carry the variant in a compound heterozygous state, and in seven who carry the variant in a heterozygous state. The p.Gly1961Glu variant is also found in a heterozygous state in two asymptomatic individuals (Allikmets et al. 1997; Wiszniewski et al. 2005; Kitiratschky et al. 2008; Cella et al. 2009; Burke et al. 2012; Burke et al. 2012; Fujinami et al. 2013; Lee et al. 2016). The p.Gly1961Glu variant is associated with a mild phenotype. Fifteen of the individuals carrying the variant exhibited bull's eye maculopathy and retinal dysfunction limited to the macula and not typical general dysfunction (Cella et al. 2009). Six individuals were found to carry additional variants in the ABCA4 gene and exhibited a more severe phenotype (Burke et al. 2012). The p.Gly1961Glu variant was absent from 220 control individuals and is reported at a frequency of 0.01498 in the South Asian population of the Exome Aggregation Consortium. Haplotype analysis in the South Asian population suggested that the p.Gly1961Glu variant has a founder effect in this population (Fujinami et al. 2013). Functional studies demonstrated that the p.Gly1961Glu variant protein resulted in reduced ATPase activity and ATP binding, while maintaining expression levels comparable to wild type, which is consistent with a mild phenotype. Additionally, the variant protein ATPase activity was inhibited by all-trans retinal, in contrast to the stimulation seen in wild type (Sun et al. 2000; Burke et al 2012a). Based on the collective evidence, the p.Gly1961Glu variant is classified as pathogenic for ABCA4-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Knight Diagnostic Laboratories, Oregon Health and Sciences University	RCV000008340	SCV000494247	pathogenic	Severe early-childhood-onset retinal dystrophy	2016-06-28	criteria provided, single submitter	clinical testing	The c.5882G>A (p.Gly1961Glu) missense variant in the ABCA4 gene has been previously reported in multiple individuals affected with Stargardt Disease (Kousal et al., 2014; Fritsche et al., 2012; Burke et al., 2012; Cella et al., 2009). This variant was observed at a significantly higher frequency in affected individuals than in a control population (OR=41.03 (5.4-310.1)). Furthermore, this variant is predicted to lie within a nucleotide binding domain, and in vitro functional assays demonstrated that this variant resulted in decreased ATP-binding capacity and ATP hydrolysis, despite an increase of the total amount of ABCA4 protein (Sun et al., 2000). Multiple in silico algorithms predict this variant to have a deleterious effect (GERP=5.35; CADD = 23.6; PolyPhen = 1.0; SIFT = 0.0). Emory Genetics Laboratory has classified this variant as Pathogenic. Therefore, this collective evidence supports the classification of the c.5882G>A (p.Gly1961Glu) as a Pathogenic variant for Stargardt Disease. We have confirmed this finding in our laboratory using Sanger sequencing.
Ambry Genetics	RCV000624210	SCV000741007	pathogenic	Inborn genetic diseases	2014-09-07	criteria provided, single submitter	clinical testing
Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University	RCV000008340	SCV000891470	likely pathogenic	Severe early-childhood-onset retinal dystrophy	2017-12-30	criteria provided, single submitter	curation
Mendelics	RCV000008340	SCV001135328	likely pathogenic	Severe early-childhood-onset retinal dystrophy	2019-05-28	criteria provided, single submitter	clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	RCV000078670	SCV001159230	pathogenic	not provided	2022-10-21	criteria provided, single submitter	clinical testing	The ABCA4 c.5882G>A; p.Gly1961Glu variant (rs1800553) has been reported in the medical literature in both the homozygous and compound heterozygous state in many individuals with ABCA4-related diseases (Allikmets 1997, Cella 2009, Garces 2018, Salles 2017, Wiszniewski 2005). Studies on individuals homozygous for this variant indicate that it is most often associated with milder, later onset retinal disease (Burke 2012). The variant is described as pathogenic or likely pathogenic by several sources in the ClinVar database (Variation ID: 7888). The variant is also described as one of the most common pathogenic variant in Stargardt patients (Burke 2012) and is found in the general population with an overall allele frequency of 0.5% (1291/282848 alleles, including 10 homozygotes) and an allele frequency of 1.4% (422/30614 alleles) in the South Asian population in the Genome Aggregation Database. The glycine at this position is highly conserved and computational algorithms predict this variant is deleterious. In support of this prediction, functional studies show this variant lies in a critical functional domain and results in reduced function of this variant protein compared to the wild type protein (Garces 2018, Sun 2000). Considering available information, this variant is classified as pathogenic but may result in a milder clinical phenotype. References: Allikmets R et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science. 1997 Sep 19;277(5333):1805-7. Burke TR et al. Retinal phenotypes in patients homozygous for the G1961E mutation in the ABCA4 gene. Invest Ophthalmol Vis Sci. 2012 Jul 3;53(8):4458-67. Cella W et al. G1961E mutant allele in the Stargardt disease gene ABCA4 causes bull's eye maculopathy. Exp Eye Res. 2009 Jun 15;89(1):16-24 Garces F et al. Correlating the Expression and Functional Activity of ABCA4 Disease Variants With the Phenotype of Patients With Stargardt Disease. Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2305-2315. Salles MV et al. Novel Complex ABCA4 Alleles in Brazilian Patients With Stargardt Disease: Genotype-Phenotype Correlation. Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5723-5730 Sun H et al. Biochemical defects in ABCR protein variants associated with human retinopathies. Nat Genet. 2000 Oct;26(2):242-6. Wiszniewski W et al. ABCA4 mutations causing mislocalization are found frequently in patients with severe retinal dystrophies. Hum Mol Genet. 2005 Oct 1;14(19):2769-78
Invitae	RCV000078670	SCV001229561	pathogenic, low penetrance	not provided	2024-01-31	criteria provided, single submitter	clinical testing	This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 1961 of the ABCA4 protein (p.Gly1961Glu). This variant is present in population databases (rs1800553, gnomAD 2.3%), including at least one homozygous and/or hemizygous individual. This variant has been observed in many individuals with autosomal recessive Stargardt disease, and has been found in trans (on the opposite chromosome) from many different pathogenic variants (PMID: 28559085, 28181551, 30060493, 19074458, 29555955). This variant appears to be significantly enriched in individuals with Stargardt compared to the general population (PMID: 28327576). In addition, in a large meta-analysis, this variant conferred a 3.2-fold increased risk (95% CI: 1.74–5.95) for age-related macular degeneration in heterozygous carriers (PMID: 25921964). This variant appears to be associated with milder and/or later onset disease (PMID: 28327576, 28446513). ClinVar contains an entry for this variant (Variation ID: 7888). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ABCA4 function (PMID: 11017087, 29847635). In summary, this variant is reported to cause disease. However, because this variant is associated with a milder form of disease than other pathogenic alleles in the ABCA4 gene, and because it is found in homozygosity in healthy individuals, it has been classified as Pathogenic (low penetrance).
Blueprint Genetics	RCV000505149	SCV001240512	pathogenic	Retinal dystrophy	2019-08-17	criteria provided, single submitter	clinical testing
CeGaT Center for Human Genetics Tuebingen	RCV000078670	SCV001247601	pathogenic	not provided	2024-01-01	criteria provided, single submitter	clinical testing	ABCA4: PM3:Very Strong, PP1:Strong, PM5, PM2:Supporting, PP3, PS3:Supporting
Centre for Mendelian Genomics, University Medical Centre Ljubljana	RCV000678513	SCV001367829	likely pathogenic	Age related macular degeneration 2	2019-09-05	criteria provided, single submitter	clinical testing	This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: Pm1,PM5,PP3,PP5.
Hadassah Hebrew University Medical Center	RCV001254602	SCV001430593	likely pathogenic	Cone-rod dystrophy 3; Severe early-childhood-onset retinal dystrophy; Retinitis pigmentosa 19	2019-06-20	criteria provided, single submitter	clinical testing
Institute of Human Genetics, University of Leipzig Medical Center	RCV000008341	SCV001440307	pathogenic	Cone-rod dystrophy 3	2019-01-01	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV000008340	SCV001521357	pathogenic	Severe early-childhood-onset retinal dystrophy	2020-01-17	criteria provided, single submitter	clinical testing	This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
Institute of Medical Molecular Genetics, University of Zurich	RCV000008340	SCV001548126	likely pathogenic	Severe early-childhood-onset retinal dystrophy	2021-01-30	criteria provided, single submitter	clinical testing
Johns Hopkins Genomics, Johns Hopkins University	RCV000008341	SCV001573158	pathogenic	Cone-rod dystrophy 3	2021-04-14	criteria provided, single submitter	clinical testing	This ABCA4 variant (rs1800553) is among the most frequent retinal dystrophy-associated variants with an allele frequency of ~1.4% in South Asians. It has an entry in ClinVar. Individuals homozygous for p.Gly1961Glu show a range of retinal abnormalities but typically have a milder clinical presentation than individuals with additional ABCA4 variants on the opposite chromosome. This variant is located within a nucleotide binding domain of ABCA4, and functional studies demonstrate that this variant results in reduced ATPase activity9,10. This variant alone is not expected to cause CORD3. We consider c.5882G>A to be pathogenic.
Genomics England Pilot Project, Genomics England	RCV000678513	SCV001760045	pathogenic	Age related macular degeneration 2		criteria provided, single submitter	clinical testing
Genomics England Pilot Project, Genomics England	RCV001542557	SCV001760046	pathogenic	Retinitis pigmentosa 19		criteria provided, single submitter	clinical testing
Laboratory of Medical Genetics, National & Kapodistrian University of Athens	RCV000008340	SCV001976708	pathogenic	Severe early-childhood-onset retinal dystrophy	2021-10-01	criteria provided, single submitter	clinical testing	PM1, PM3, PM5, PP2, PP3, PP5
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen	RCV000787514	SCV001983384	likely pathogenic	Stargardt disease	2021-10-25	criteria provided, single submitter	clinical testing
Institute of Human Genetics, University of Leipzig Medical Center	RCV000504952	SCV002044423	pathogenic	Macular dystrophy	2021-11-22	criteria provided, single submitter	clinical testing	This variant was identified aspotentially compound heterozygous with NM_000350.3:c.3113C>T and NM_000350.3:c.1622T>C. Criteria applied: PM3_VSTR, PS3_SUP, PM5_STR, PP3
Institute of Human Genetics, University Hospital Muenster	RCV001807001	SCV002054127	pathogenic	Cone-rod dystrophy	2019-04-23	criteria provided, single submitter	clinical testing	ACMG categories: PS3,PM1,PM3,PP3,PP4
3billion	RCV000008340	SCV002058783	likely pathogenic	Severe early-childhood-onset retinal dystrophy	2022-01-03	criteria provided, single submitter	clinical testing	Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000007888, PMID:9295268, PS1_S). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000236140, PMID:22427542,NULL, PM5_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.76, 3CNET: 0.857, PP3_P). A missense variant is a common mechanism associated with Stargardt disease 1 (PP2_P). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline.
Genome-Nilou Lab	RCV000008340	SCV002100408	pathogenic	Severe early-childhood-onset retinal dystrophy	2021-09-10	criteria provided, single submitter	clinical testing
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard	RCV002247269	SCV002520430	likely pathogenic	Retinitis pigmentosa		criteria provided, single submitter	curation	The p.Gly1961Glu variant in ABCA4 was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab (https://oculargenomics.meei.harvard.edu/labs/pierce-lab/lab-members/). Through a review of available evidence we were able to apply the following criteria: PS3, PM5, PP3, PP5. Based on this evidence we have classified this variant as likely pathogenic. If you have any questions about the classification please reach out to the Pierce Lab.
Institute of Human Genetics, University of Leipzig Medical Center	RCV000008340	SCV002526676	pathogenic	Severe early-childhood-onset retinal dystrophy	2022-07-21	criteria provided, single submitter	clinical testing	_x000D_This variant was identified in a patient with another variant NM_000350.3:c.67-2A>G Criteria applied: PM3_VSTR, PM5_STR, PP1_STR, PS3_MOD, PP3, PP4
Arcensus	RCV000008340	SCV002564625	likely pathogenic	Severe early-childhood-onset retinal dystrophy	2013-02-01	criteria provided, single submitter	clinical testing
MGZ Medical Genetics Center	RCV000008340	SCV002581171	pathogenic	Severe early-childhood-onset retinal dystrophy	2022-07-26	criteria provided, single submitter	clinical testing
Variantyx, Inc.	RCV000273328	SCV002754519	pathogenic	ABCA4-related disorder	2022-11-04	criteria provided, single submitter	clinical testing	This is a nonsynonymous variant in the ABCA4 gene (OMIM 601691). Biallelic pathogenic variants in this gene have been associated with autosomal recessive ABCA4-related disorders. This variant has been reported in the homozygous or compound heterozygous state in many individuals with mild or late-onset ABCA4-related disease (PMID: 30060493, 29555955, 28559085, 19074458, 28181551) (PM3_Strong). Additionally, this variant has been shown to confer a moderate risk (~3-fold) for age-related macular degeneration (PMID: 25921964). Functional studies have shown that this variant alters ABCA4 protein function (PMID: 11017087, 29847635) (PS3). An alternate amino acid change at this position (p.Gly1961Arg) has been previously reported as pathogenic in affected individuals (PMID: 23755871, 19074458, 26780318, 28118664) (PM5). Multiple computational algorithms predict a deleterious effect for this amino acid substitution (PP3). This variant has a 1.378% maximum allele frequency in non-founder control populations (https://gnomad.broadinstitute.org/). Based on current evidence, this variant is classified as pathogenic for autosomal recessive ABCA4-related disorders.
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	RCV000008340	SCV002767263	pathogenic	Severe early-childhood-onset retinal dystrophy	2022-09-02	criteria provided, single submitter	clinical testing	Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Stargardt disease (MIM#248200) and other eye conditions (OMIM). (I) 0106 - This gene is associated with autosomal recessive disease (OMIM). (I) 0115 - Variants in this gene are known to have variable expressivity (PMID: 31522899). (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to glutamic acid. (I) 0252 - This variant is homozygous. (I) 0305 - Variant is present in gnomAD >=0.01 and <0.03 for a recessive condition (v2: 1271 heterozygotes, 10 homozygotes). (I) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (26 heterozygotes, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and high conservation. (I) 0600 - Variant is located in the annotated NBD2 domain (PMID: 29847635). (I) 0701 - Other missense variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. p.(Gly1961Ala) has been previously reported in patients with Stargardt disease (ClinVar, PMID: 22427542). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals with mild and later onset Stargardt disease (ClinVar, PMID: 22661473, PMID: 28327576, PMID: 28130426, PMID: 29925512). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function, where transfected cells displayed reduced ATPase activity and substrate binding (PMID: 29847635). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Intergen, Intergen Genetics and Rare Diseases Diagnosis Center	RCV003324710	SCV004030451	pathogenic	ABCA4-related retinopathy	2023-08-29	criteria provided, single submitter	clinical testing
Neuberg Centre For Genomic Medicine, NCGM	RCV000008340	SCV004048390	pathogenic	Severe early-childhood-onset retinal dystrophy		criteria provided, single submitter	clinical testing	This variant c.5882G>A (p.Gly1961Glu) in ABCA4 gene has been observed in many individuals with autosomal recessive Stargardt disease, and has been found in trans (on the opposite chromosome) from many different pathogenic variants (PMID: Stone et al., 2017; Riera et al., 2017). This variant is present in population databases (rs1800553, ExAC 1.5%), including several homozygous individuals, and has an allele count higher than expected for a pathogenic variant (Kobayashi et al., 2017). However, this variant appears to be significantly enriched in individuals with Stargardt compared to the general population (Lee et al., 2017). This variant appears to be associated with milder and/or later onset disease (Lee et al., 2017). This variant has been reported to affect ABCA4 protein function (Sun et al. 2000). The amino acid Gly at position 1961 is changed to a Glu changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by SIFT and the residue is conserved across species. The amino acid change p.Gly1961Glu in ABCA4 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.
PreventionGenetics, part of Exact Sciences	RCV000273328	SCV004109410	pathogenic	ABCA4-related disorder	2024-01-18	criteria provided, single submitter	clinical testing	The ABCA4 c.5882G>A variant is predicted to result in the amino acid substitution p.Gly1961Glu. This variant has been reported many times in the compound heterozygous state in individuals with retinal dystrophy and has been associated with later-onset and milder retinal phenotypes (see for examples Cella et al. 2009. PubMed ID: 19217903, Lewis et al. 1999. PubMed ID: 9973280, Allikmets et al. 1997. PubMed ID: 9295268, Fujinami et al. 2013. PubMed ID: 23769331). This variant is documented with a global allele frequency of 0.46% in gnomAD, including several homozygotes (http://gnomad.broadinstitute.org/variant/1-94473807-C-T). This allele frequency is relatively high and consistent with this variant causing a more mild and later-onset retinal phenotype (Burke et al. 2012. PubMed ID: 22661473). However, when this variant is present in cis with other pathogenic ABCA4 variants as a complex allele, it has been reported to cause severe retinal phenotypes (Burke et al. 2012. PubMed ID: 22661473). Given the evidence, we interpret c.5882G>A (p.Gly1961Glu), both alone and as part of a complex allele, as pathogenic.
Dept Of Ophthalmology, Nagoya University	RCV000505149	SCV004706492	pathogenic	Retinal dystrophy	2023-10-01	criteria provided, single submitter	research
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center	RCV000008340	SCV004806246	likely pathogenic	Severe early-childhood-onset retinal dystrophy	2024-03-25	criteria provided, single submitter	clinical testing
OMIM	RCV000008339	SCV000028547	risk factor	MACULAR DEGENERATION, AGE-RELATED, 2, SUSCEPTIBILITY TO	2008-07-01	no assertion criteria provided	literature only
OMIM	RCV000008340	SCV000028548	pathogenic	Severe early-childhood-onset retinal dystrophy	2008-07-01	no assertion criteria provided	literature only
OMIM	RCV000008341	SCV000028549	pathogenic	Cone-rod dystrophy 3	2008-07-01	no assertion criteria provided	literature only
Retina International	RCV000078670	SCV000117911	not provided	not provided		no assertion provided	not provided
NEI Ophthalmic Genomics Laboratory, National Institutes of Health	RCV000078670	SCV000119180	not provided	not provided		no assertion provided	not provided
Division of Human Genetics, Children's Hospital of Philadelphia	RCV000008341	SCV000536764	pathogenic	Cone-rod dystrophy 3	2016-06-10	no assertion criteria provided	research
NIHR Bioresource Rare Diseases, University of Cambridge	RCV000504952	SCV000599002	likely pathogenic	Macular dystrophy	2015-01-01	no assertion criteria provided	research
NIHR Bioresource Rare Diseases, University of Cambridge	RCV000505149	SCV000599003	likely pathogenic	Retinal dystrophy	2015-01-01	no assertion criteria provided	research
GenomeConnect, ClinGen	RCV000008340	SCV000607275	not provided	Severe early-childhood-onset retinal dystrophy		no assertion provided	phenotyping only	GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+	RCV000678513	SCV000804584	pathogenic	Age related macular degeneration 2	2016-09-01	no assertion criteria provided	clinical testing
Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet	RCV000787514	SCV000926482	pathogenic	Stargardt disease	2018-04-01	no assertion criteria provided	research
Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet	RCV000504952	SCV000926781	likely pathogenic	Macular dystrophy	2018-04-01	no assertion criteria provided	research
Sharon lab, Hadassah-Hebrew University Medical Center	RCV000787514	SCV001160823	pathogenic	Stargardt disease	2019-06-23	no assertion criteria provided	research
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV000078670	SCV001549384	pathogenic	not provided		no assertion criteria provided	clinical testing	The ABCA4 p.Gly1961Glu variant was identified in the literature in several homozygous or compound heterozygous individuals with ABCA4-related conditions (Stargardt disease 1, autosomal recessive retinitis pigmentosa, cone-rod dystrophy); this variant is typically associated with a milder phenotype and late-onset disease (Cella_2009_PMID:19217903; Burke_2012_PMID:22661473; Wiszniewski_2005_PMID:16103129; Kaway_2017_PMID:28611652; Zernant_2018_PMID:29848554). Furthermore, this variant is also seen to segregate with autosomal recessive retinitis pigmentosa, as seen in a large consanguineous family where this variant was identified in three affected compound heterozygotes (Ducroq_2006_PMID:16896346). The variant was identified in dbSNP (ID: rs1800553) and ClinVar (classified as pathogenic by Laboratory for Molecular Medicine, GeneDx and ten other laboratories, and as likely pathogenic by Mendelics and four other laboratories). The variant was identified in control databases in 1291 of 282848 chromosomes (10 homozygous) at a frequency of 0.004564 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Ashkenazi Jewish in 242 of 10368 chromosomes (freq: 0.02334), South Asian in 422 of 30614 chromosomes (freq: 0.01378), Other in 41 of 7222 chromosomes (freq: 0.005677), European (non-Finnish) in 488 of 129158 chromosomes (freq: 0.003778), Latino in 68 of 35440 chromosomes (freq: 0.001919), European (Finnish) in 15 of 25124 chromosomes (freq: 0.000597), African in 10 of 24970 chromosomes (freq: 0.000401), and East Asian in 5 of 19952 chromosomes (freq: 0.000251). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.Gly1961 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein. Further, functional analysis has demonstrated that this variant results in reduced basal and retinal-stimulated ATPase activities compared to control (Sun_2000_PMID:11017087). In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
Clinical Genetics, Academic Medical Center	RCV000078670	SCV001917731	pathogenic	not provided		no assertion criteria provided	clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+	RCV000078670	SCV001953887	pathogenic	not provided		no assertion criteria provided	clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	RCV000078670	SCV001969246	pathogenic	not provided		no assertion criteria provided	clinical testing
Al Jalila Children's Genomics Center, Al Jalila Childrens Speciality Hospital	RCV001731281	SCV001984722	benign	not specified	2020-02-11	flagged submission	clinical testing